eNews - Nov. 2007 CellGenix Technologie Transfer GmbH Am Flughafen 16 79108 Freiburg (Germany)

CellGenix, the world leading manufacturer of GMP cytokines for Clinical Cell Therapy Applications, announces the launch of its newest & standard-setting GMP product:

NEW: CellGro^® GMP IL-15 (for ex vivo use)

Product Description

• recombinant human Interleukin 15 (for ex vivo use)
• produced in E.coli
• manufactured according to Good Manufacturing Practise (GMP)
• animal derived component free (ADCF) in production & purification
• excellent activity and performance
• lyophilized without stabilizers
• available in 50 µg vials

Areas of Application

• Differentiation and expansion of T-cells
• Activation and proliferation of NK cells

In addition to our cytokines for:

• Dendritic Cell generation (IL-4, GM-CSF, TNF-alpha, IL-1beta, IL-6)
• Hematopoietic stem and progenitor cell expansion (SCF*, TPO*, Flt3-L*, IL-3*)
• Mesenchymal stem cell expansion & chondrocyte cultivation (bFGF*)

Our cytokines are available either in GMP-grade or research-grade (*: currently in research-grade only). CellGenix is continuously developing further cytokines for the successful application in clinical cell therapy.

Interested?

Please give our Customer Service a call: +49 (0)761 / 88889-330
or send an email to: info@cellgenix.com.

CellGro^® is a registered trade mark in several European countries and Japan.
In the U.S.A. and Canada CellGro^® products are distributed under the name of CellGenix™.

Download or print this eNews as PDF